Get started
Candel Therapeutics, Inc.CC

Candel Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

CADL chart


Full chart

Key facts today


Candel Therapeutics will present positive Phase 3 results for CAN-2409 in localized prostate cancer at the 2025 ASCO Annual Meeting, highlighting data from a key clinical trial.
Analyze the impactAnalyze the impact

CADL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪224.84 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.75 USD
Net income (FY)
‪−55.18 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪34.58 M‬
Beta (1Y)
1.32

Employees


Employees (FY)
38
Change (1Y)
−4 −9.52%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.45 M‬ USD

About Candel Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Paul-Peter Tak
Website
candeltx.com
Headquarters
Needham
Founded
2002
FIGI
BBG00N0D4Z71
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CADL news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CADL is 5.00 USD — it has increased by 0.53% in the past 24 hours. Watch Candel Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Candel Therapeutics, Inc. stocks are traded under the ticker CADL.
CADL stock has fallen by −2.46% compared to the previous week, the month change is a −44.65% fall, over the last year Candel Therapeutics, Inc. has showed a −17.22% decrease.
We've gathered analysts' opinions on Candel Therapeutics, Inc. future price: according to them, CADL price has a max estimate of 25.00 USD and a min estimate of 15.00 USD. Watch CADL chart and read a more detailed Candel Therapeutics, Inc. stock forecast: see what analysts think of Candel Therapeutics, Inc. and suggest that you do with its stocks.
CADL reached its all-time high on Sep 8, 2021 with the price of 14.78 USD, and its all-time low was 0.66 USD and was reached on Nov 3, 2023. View more price dynamics on CADL chart.
See other stocks reaching their highest and lowest prices.
CADL stock is 9.94% volatile and has beta coefficient of 1.32. Track Candel Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Candel Therapeutics, Inc. there?
Today Candel Therapeutics, Inc. has the market capitalization of ‪224.84 M‬, it has decreased by −8.05% over the last week.
Yes, you can track Candel Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Candel Therapeutics, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
CADL earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.23 USD resulting in a −75.74% surprise. The estimated earnings for the next quarter are −0.37 USD per share. See more details about Candel Therapeutics, Inc. earnings.
Candel Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CADL net income for the last quarter is ‪−14.07 M‬ USD, while the quarter before that showed ‪−10.65 M‬ USD of net income which accounts for −32.19% change. Track more Candel Therapeutics, Inc. financial stats to get the full picture.
No, CADL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 38 employees. See our rating of the largest employees — is Candel Therapeutics, Inc. on this list?
Like other stocks, CADL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Candel Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Candel Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Candel Therapeutics, Inc. stock shows the neutral signal. See more of Candel Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.